Developing a cure for Black Bone Disease by Nicolas T Sireau
MEETING ABSTRACT Open Access
Developing a cure for Black Bone Disease
Nicolas T Sireau
From 6th European Conference on Rare Diseases and Orphan Products
Brussels, Belgium. 23-25 May 2012
Alkaptonuria (AKU for short) was the first genetic disease
ever identified as such, by Dr Archibald Garrod in 1901 in
London [1]. It is a rare disease affecting approximately one
in 250,000 people, apart from countries such as Slovakia,
Jordan and parts of South India where the number is up
to 10 times higher [2]. Alkaptonuria is a monogenic dis-
ease leading to an enzyme deficiency, causing the accumu-
lation of homogentisic acid (HGA) at 2,000 times the
normal rate [3]. The HGA binds to cartilage and bone and
pigments, turning it black in a process called ochronosis -
hence its name of Black Bone Disease. The AKU Society, a
patient advocacy group, has worked in close partnership
with the Royal Liverpool University Hospital and the Uni-
versity of Liverpool over the past nine years to develop a
major programme of research and treatment. This started
with the post-mortem of an AKU patient [4], funded
through sponsored events, followed by the funding of a
PhD programme that developed an in vitro model of AKU
[5]. Thanks to support from the Big Lottery Fund, the
AKU Society then funded a four-year programme at UoL
that successfully created an animal model of AKU, in
which new therapies are being tested. The AKU Society
and RLUH in parallel launched a global campaign to iden-
tify AKU patients [6], starting with three patients in the
UK and reaching more than 1,000 patients globally by
2012. AKU patients and their families set up formal AKU
Societies in the UK, France, Germany, the Netherlands,
Italy, the USA and Canada in order to build the patient
movement. A study was carried out to find out the average
cost of an AKU patient to the National Health Service:
£100,000 a year. This was used to build a case to the NHS
for funding the National Alkaptonuria Society at RLUH
and launching it in June 2012. The AKU Society, RLUH
and UoL led the creation of an international consortium
including 15 pharma companies, biotechs, universities,
clinical trial centres, patient groups and contract research
organisations in eight countries across Europe and North
America. Thanks to funding from the European Commis-
sion, this consortium will launch in late 2012 a five-and-a-
half year clinical development programme to develop and
obtain marketing authorisation for nitisinone, a small
molecule that inhibits the accumulation of homogentisic
acid. Further AKU research centres have also been estab-
lished in Jordan and South India.
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